Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-News: RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-News: RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues
DGAP-News: RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro
Acadia Healthcare Names R. David Kelly to Board of Directors
Acadia Healthcare Names R. David Kelly to Board of Directors


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that R. David Kelly has been appointed to serve as an independent director on the Company’s Board of Directors.


This press release

Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease
Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India
DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: Financial year 2022 again marked by COVID-19 pandemic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: Financial year 2022 again marked by COVID-19 pandemic
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: Financial year 2022 again marked by COVID-19 pandemic
Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution
Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution
DGAP-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23735/Rhoen-klinikum.svg.png
DGAP-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable
DGAP-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable
AMN Healthcare CEO Susan Salka Recognized as One of 100 Most Influential People by Modern Healthcare
AMN Healthcare CEO Susan Salka Recognized as One of 100 Most Influential People by Modern Healthcare


Susan Salka, Chief Executive Officer of AMN Healthcare, was recognized by Modern Healthcare as one of the 100 Most Influential People in Healthcare for 2021, a year of unprecedented stress for

AMN Healthcare Names Jorge Caballero to Board of Directors
AMN Healthcare Names Jorge Caballero to Board of Directors


AMN Healthcare (NYSE: AMN) today announced the Board of Directors has appointed Jorge A. Caballero as a new independent director.


This press release features multimedia. View the full release

AMN Healthcare Board Members Sylvia Trent-Adams and Daphne E. Jones Named to Savoy Magazine’s Most Influential Black Corporate Directors
AMN Healthcare Board Members Sylvia Trent-Adams and Daphne E. Jones Named to Savoy Magazine’s Most Influential Black Corporate Directors


Two members of the AMN Healthcare Board of Directors – Daphne E. Jones and Sylvia Trent-Adams -- have been named to Savoy Magazine’s prestigious 2021 list of Most Influential Black Corporate

Sartorius: Unternehmen profitiert von der Corona-Krise
Sartorius: Unternehmen profitiert von der Corona-Krise

Ein absoluter Highflyer am deutschen Aktienmarkt ist schon seit vielen Jahren die Vorzugsaktie des Göttinger Laborausrüsters Sartorius (WKN: 716563). Dies ist umso erstaunlicher, da noch zu Neuer

Premier, Inc. Declares Quarterly Cash Dividend: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. Declares Quarterly Cash Dividend


Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.21 per share of Class A common

Sonova announces two new hearing aid platforms, including the first hearing aid with real-time AI to address most pressing need in hearing loss
Sonova announces two new hearing aid platforms, including the first hearing aid with real-time AI to address most pressing need in hearing loss
Sonova announces two new hearing aid platforms, including the first hearing aid with real-time AI to address most pressing need in hearing loss
Chemed Corporation Declares Quarterly Dividend of 50 Cents:
Chemed Corporation Declares Quarterly Dividend of 50 Cents


Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 50-cents per share on the Company’s capital stock, payable on August 30, 2024, to

Acadia Healthcare Reports Second Quarter 2024 Results: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Reports Second Quarter 2024 Results


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter and six months ended June 30, 2024.



Second Quarter Highlights




  • Revenue totaled $796.0

LivaNova Reports Second-Quarter 2024 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Reports Second-Quarter 2024 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended June 30, 2024 and raised full-year 2024 revenue and adjusted diluted earnings

Chemed Reports Second-Quarter 2024 Results:
Chemed Reports Second-Quarter 2024 Results


Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest

Premier, Inc. to Report Fiscal 2024 Fourth-Quarter and Full-Year Results and Host Conference Call on August 20, 2024: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier, Inc. to Report Fiscal 2024 Fourth-Quarter and Full-Year Results and Host Conference Call on August 20, 2024


Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 fourth quarter and full year on Tuesday, August 20, 2024, at approximately 6:30 a.m. ET. The

Acadia Healthcare Announces Date for Second Quarter 2024 Earnings Release: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Announces Date for Second Quarter 2024 Earnings Release


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2024 results on Wednesday, July 31, 2024, after the close of the market. Acadia will conduct a

Chemed To Report Second-Quarter 2024 Earnings July 24, Related Conference Call To Be Held On July 25:
Chemed To Report Second-Quarter 2024 Earnings July 24, Related Conference Call To Be Held On July 25


Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the second quarter ended June 30, 2024, on Wednesday, July 24, 2024, following the close of trading on the

LivaNova to Announce Second-Quarter 2024 Results: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Announce Second-Quarter 2024 Results


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8

Annual General Shareholders’ Meeting 2024:
Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2024: Sonova shareholders approve all motions of the Board of Directors
Annual General Shareholders’ Meeting 2024: Sonova shareholders approve all motions of the Board of Directors
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of